About
Pressroom
Resources
Get Updates
Issues
Access to Medicines
Funding the Fight
Health Justice
Transparency & Accountability
Blog
Our Impact
Take Action
Do something now
DONATE
Access to Medicines
Access to Medicines
New ViiV license with the Medicines Patent Pool expands access but eviscerates transparency
Access to Medicines
South Africa and India’s Proposal to Waive Recognition and Enforcement of Intellectual Property Rights for C...
Access to Medicines
Moderna Responds to Activist Pressure, But In the Race for Our Lives, We Need More Than Baby Steps
Access to Medicines
In Addition to Outrageous Prices and Preferential Supply to the US only, Gilead’s Allowance for Compulsory L...
Access to Medicines
U.S.-, China- and EU-First Nationalism and COVID-19 Technology Hoarding Push the Rest of the World to the End ...
Access to Medicines
Gilead Remdesivir Licenses: Half Measures are Not Nearly Good Enough
Access to Medicines
Without a Global Approach to Deadly Inequities in Access to Possible COVID-19 Treatments and Vaccines, Legisla...
Access to Medicines
Expect a Wave of Pro-IP Proposals from Industry in the Wake of the COVID-19
Access to Medicines
Drug Companies are Running Scared – Let’s Make Them Run Faster
Access to Medicines
Rationale for Supporting Costa Rica’s Proposal for Emergency COVID-19 Technology IP Pool for All Countries
Access to Medicines
Protesting for Pediatric Treatment: an Interview with Maurine Murenga
Access to Medicines
Generic Licensing: the Only Path Through the Maze of Gilead and U.S. Patents that Achieves Access to Affordabl...
Access to Medicines
House Democrats Must Include Generic Licensing Provisions in H.R. 3 in Order to Deliver a Meaningful Check on...
Access to Medicines
The “Lower Drug Costs Now Act of 2019”: What’s Good, What’s Bad, and What Must be Improved
Access to Medicines
Fact Checking Trump’s Drug Pricing Claims in State of the Union
SEE MORE
